News
$Puma Biotechnology(PBYI.US$ • Puma Biotechnology (NASDAQ:PBYI) announced Wednesday that the U.S. FDA has greenlighted a Phase 2 trial to investigate its oral kinase inhibitor alisertib, in-licensed from Takeda (NYSE:TAK), in patients with breast cancer.
• The study named ALISCA-Breast1 is designed to evaluate alisertibin combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn’t undergone chemotherapy.
• According to the company’s Investigational New Drug Application (IND), the trial will be designed to evaluate the therapeutic combo as a late-line option for the patient group. Puma Biotechnology (PBYI) plans to start ALISCA-Breast1 in H2 2024.
• The study named ALISCA-Breast1 is designed to evaluate alisertibin combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn’t undergone chemotherapy.
• According to the company’s Investigational New Drug Application (IND), the trial will be designed to evaluate the therapeutic combo as a late-line option for the patient group. Puma Biotechnology (PBYI) plans to start ALISCA-Breast1 in H2 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
